분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-08-29 02:53:15 , Hit : 2133
 Daclatasvir (Daklinza) for Chronic Hepatitis C Cleared in EU


Megan Brooks
DisclosuresAugust 27, 2014


Editors' Recommendations
EU Panel Endorses Daclatasvir (Daklinza) for Chronic Hep C
New Hepatitis C Guidelines Are Evolving Documents
HCV Therapy: High Rate of Viral Clearance, No Injections



Receive an email from Medscape whenever new articles on this topic are available.
Personal Alert  Add Hepatitis C to My Topic Alert

Drug & Reference Information
Hepatitis C Test
Chronic Hepatitis C Pathology
Pediatric Hepatitis C

The European Commission has approved daclatasvir (Daklinza, Bristol-Myers Squibb) to treat adults with chronic hepatitis C virus (HCV) infection in combination with other drugs, the company announced today.

The approval follows an endorsement in June by the European Medicines Agency Committee for Medicinal Products for Human Use.

Daclatasvir blocks the action of NS5A, a protein essential for HCV replication. It is indicated for adults infected with HCV genotypes 1, 2, 3, and 4.

In a news release, the company notes that oral daclatasvir in combination with oral sofosbuvir provided cure rates of up to 100% in clinical trials, including in patients with advanced liver disease, genotype 3, and those who have previously failed treatment with protease inhibitors.

Daclatasvir is the first NS5A complex inhibitor approved in the European Union (EU) and, in combination with other drugs, provides a "shorter treatment duration (12 or 24 weeks) compared to 48 weeks of treatment with interferon- and ribavirin-based regimens," the company says.

Across clinical studies, daclatasvir-based regimens have been generally well-tolerated, with low discontinuation rates. The most common adverse effects with daclatasvir when used in combination with other drugs are fatigue, headache, and nausea.

The safety of daclatasvir has been demonstrated in diverse patient populations that include elderly patients, patients with advanced liver disease, post–liver transplant recipients, and patients coinfected with HIV, the company says.

"HCV is a challenging virus to overcome," Michael P. Manns, MD, professor and chairman, Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Germany, said in the release. Daclatasvir, when combined with other compounds, "often results in cure among even the hardest-to-treat patients," he added.

Recommended regimens and treatment durations for daclatasvir-based regimens include:

For HCV genotype 1 or 4 without cirrhosis: daclatasvir plus sofosbuvir for 12 weeks. Consider prolongation to 24 weeks for patients with prior treatment, including a NS3/4A protease inhibitor.


For genotype 1 or 4 with compensated cirrhosis: daclatasvir plus sofosbuvir for 24 weeks. Consider shortening treatment to 12 weeks for previously untreated patients with cirrhosis and positive prognostic factors such as IL28B CC genotype and/or low baseline viral load. Consider adding ribavirin for patients with very advanced liver disease or with other negative prognostic factors, such as prior treatment experience.


For genotype 3 with compensated cirrhosis and/or treatment experienced: daclatasvir plus sofosbuvir plus ribavirin for 24 weeks.


For genotype 4: 24 weeks of daclatasvir plus 24 to 48 weeks of peginterferon alfa and ribavirin. If the patient has HCV RNA undetectable at both treatment weeks 4 and 12, all 3 components of the regimen should be continued for 24 weeks. If the patient achieves undetectable HCV RNA, but not at both treatment weeks 4 and 12, daclatasvir should be discontinued at 24 weeks and peginterferon alfa and ribavirin continued for a total duration of 48 weeks.


Daclatasvir monotherapy is not recommended. The Summary of Product Characteristics will be available online. Commercial availability of daclatasvir in the EU will be determined by individual member states.







947   Gilead Licenses Hepatitis Therapy in India Amid Price Criticism  이성욱 2014/09/17 1704
946   자신의 유전체를 해체하고 재조립하는 단일 세포  이성욱 2014/09/15 1449
945   STAP세포논문철회에서 새롭게 밝혀진 사실들  이성욱 2014/09/15 1305
944   질 속의 미생물(vaginal microbe)이 생성하는 새로운 항생제  이성욱 2014/09/15 1480
943   자연계의 항생제 공장에서 스위치 역할을 하는 소분자 물질  이성욱 2014/09/04 1945
  Daclatasvir (Daklinza) for Chronic Hepatitis C Cleared in EU  이성욱 2014/08/29 2133
941   소아암 촉진 유전자 Lin28b 규명  이성욱 2014/08/18 1461
940   바이러스를 저지시키는 방법  이성욱 2014/08/15 1650
939   Sovaldi forces Incivek off the hep C market as Vertex calls it quits  이성욱 2014/08/15 1509
938   Genetically 'edited' fruit could soon hit supermarket shelves  이성욱 2014/08/15 1324
937   암 연구를 위한 새로운 유전자 편집 기술  이성욱 2014/08/11 1450
936   New Guide RNAs for CRISPR Can Double the Targetable Genome  이성욱 2014/08/09 2142
935   일본의 뇌과학자 요시키 사사이의 죽음  이성욱 2014/08/08 1767
934   Roche says to buy Danish Santaris for up to $450 million  이성욱 2014/08/06 1302
933   뇌종양이 남성에서 더 흔한 이유?  이성욱 2014/08/06 1654
932   서아프리카의 에볼라 사태, 전 지구적 재앙으로 이어질 수 있을까?  이성욱 2014/08/06 1532
931   가장 중요한 감시자 p53의 새로운 기능!  이성욱 2014/08/05 1420
930   HIV를 죽게하는 강제적인 돌연변이  이성욱 2014/08/04 1460
929   「신약승인을 위한 임상시험 데이터」, 공개해야 하나?  이성욱 2014/08/01 1457
928   miRNA를 이용한 계통발생 분석의 문제점  이성욱 2014/08/01 1667

[이전 10개] [1]..[11][12][13][14][15][16] 17 [18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN